StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)

Tue, 09 Jun 2026 06:47:19 -0400

H.C. Wainwright analyst Mitchel Kapoor reiterated a Buy rating and $70.00 price target on Neurogene (NASDAQ: NGNE).

The analyst commented: "Neurogene dosed 25 participants in Embolden, above the initial target of 20, with the first 24 comprising the pre-specified ITT population for the primary analysis and the 25th patient adding safety and durability follow-up. This clears the near-term execution milestone highlighted after our BioConnect fireside chat in May and keeps NGN-401 aligned with the BLA timeline. The primary analysis will occur after the 24 ITT participants complete 12 months of follow-up, with topline Embolden data expected 2H27. The efficacy threshold remains

Form 8-K Neurogene Inc. For: Jun 08

Mon, 08 Jun 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260608/26614343.html

Form 8-K Neurogene Inc. For: Jun 08

Mon, 08 Jun 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260608/26614343.html

Neurogene completes dosing in gene therapy trial for Rett syndrome

Mon, 08 Jun 2026 07:31:07 -0400

Neurogene Inc. (NASDAQ: NGNE) announced it has completed dosing in its Embolden registrational trial of NGN-401, a gene therapy for Rett syndrome. The company dosed 25 participants, exceeding its initial target of 20 due to demand from the Rett syndrome community.

The trial's statistical analysis plan had pre-specified an intent-to-treat population of up to 24 participants. Neurogene elected to overenroll and dose all eligible participants already in screening to ensure timely completion of dosing.

Embolden is a multi-center, single-arm, open-label, baseline-controlled registrational trial evaluating the efficacy, safety and tolerability of a one-time dose of NGN-401 at 1E15 vg in females with Rett

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Mon, 08 Jun 2026 07:30:00 -0400

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Topline data from Embolden anticipated in 2H 2027

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Mon, 08 Jun 2026 07:30:00 -0400

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Topline data from Embolden anticipated in 2H 2027

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Mon, 08 Jun 2026 07:30:00 -0400

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Topline data from Embolden anticipated in 2H 2027

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Mon, 08 Jun 2026 07:30:00 -0400

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Topline data from Embolden anticipated in 2H 2027

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to

Form 8-K Neurogene Inc. For: Jun 03

Thu, 04 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260604/26606381.html

Form 8-K Neurogene Inc. For: Jun 03

Thu, 04 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260604/26606381.html

Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70

Wed, 03 Jun 2026 06:42:31 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Neurogene (NASDAQ: NGNE) with a Buy rating and a price target of $70.00.

The analyst comments "We initiate coverage of Neurogene (NGNE) with a Buy rating and $70 price target, implying ~170% upside from current levels. NGNE’s lead asset, NGN‑401, is a one‑time, ICV‑delivered AAV9 gene therapy for Rett syndrome, a rare neurodevelopmental disorder with no disease‑modifying treatments. NGN-401 is being evaluated in the Ph3 EMBOLDEN trial, with dosing expected to complete shortly and 12‑month topline data anticipated in 2H27. The company’s ~$243M cash balance is guided to fund operations past this

Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70

Wed, 03 Jun 2026 06:42:31 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Neurogene (NASDAQ: NGNE) with a Buy rating and a price target of $70.00.

Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70

Wed, 03 Jun 2026 06:42:31 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Neurogene (NASDAQ: NGNE) with a Buy rating and a price target of $70.00.

Rodman & Renshaw Starts Neurogene (NGNE) at Buy, PT $70

Wed, 03 Jun 2026 06:42:31 -0400

Rodman & Renshaw analyst Seema Sheoran initiates coverage on Neurogene (NASDAQ: NGNE) with a Buy rating and a price target of $70.00.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 1, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene (NGNE) PT Raised to $65 at Craig-Hallum

Fri, 15 May 2026 09:42:57 -0400

Craig-Hallum analyst Albert Lowe raised the price target on Neurogene (NASDAQ: NGNE) to $65.00 (from $50.00) while maintaining a Buy rating.

Neurogene (NGNE) Misses Q1 EPS by 139c

Tue, 12 May 2026 17:28:46 -0400

Neurogene (NASDAQ: NGNE) reported Q1 EPS of ($1.39).

For earnings history and earnings-related data on Neurogene (NGNE) click here.

Form 8-K Neurogene Inc. For: May 12

Tue, 12 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26477783.html

Form 8-K Neurogene Inc. For: May 12

Tue, 12 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260512/26477783.html

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 12 May 2026 16:05:00 -0400

Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401

Strong cash position provides runway through first quarter of 2028

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases,

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 12 May 2026 16:05:00 -0400

Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401

Strong cash position provides runway through first quarter of 2028

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases,

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Tue, 12 May 2026 16:05:00 -0400

Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026

NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026

Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401

Strong cash position provides runway through first quarter of 2028

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases,